Stem cells and hair loss: can they really make hair grow?

First: hair is not dead

When we see a hair outside the scalp, it looks like nothing more than a fiber. But beneath the skin lies a complex structure: the hair follicle. Inside the follicle we find epithelial cells, dermal papilla cells, melanocytes, blood vessels, nerves, immune cells, and also follicular stem cells. These stem cells play a role in the follicle's extraordinary capacity to produce a new hair again and again.

The follicle has its own 'reservoir' of stem cells

There is a region of the follicle called the bulge, or follicular protuberance. A population of epithelial stem cells resides there. These cells remain relatively quiescent during certain phases, but when they receive the right signals they become activated and participate in follicle regeneration during the new growth cycle. This is one of the reasons why hair is a fascinating model for regenerative medicine.

Hair does not grow continuously

Each follicle goes through a cycle. The anagen phase is the active growth phase, during which the hair elongates. The catagen phase is a short transitional phase. The telogen phase is the resting phase. And the exogen phase is the moment when the hair finally falls out. Afterwards, if the follicle remains functional, a new cycle begins. The fundamental question in alopecia is: what is going wrong in that cycle?

Not all alopecias share the same problem

This is essential. Androgenetic alopecia is not the same as telogen effluvium, alopecia areata, lichen planopilaris, frontal fibrosing alopecia, cicatricial alopecia, or iron deficiency. Therefore, no stem cell technology can be 'the treatment for hair loss' in general. First, we need a diagnosis.

Let's start with androgenetic alopecia

It is the most common form of alopecia and can appear in both men and women. In predisposed individuals, certain follicles progressively respond to androgenic signals. The result is miniaturization: each new hair grows increasingly thinner, shorter, and less pigmented, until the follicle ultimately produces an almost invisible hair.

Is the follicle dead?

Not necessarily, and that is precisely what makes this interesting. In many stages of androgenetic alopecia the follicle is still present: it is miniaturized, not destroyed. That means a biological opportunity to modify its behavior still exists. And it is exactly here that interest in regenerative therapies is born.

What do stem cells have to do with this?

There are two broad strategies. The first involves using cells. The second involves using the signals those cells produce. And currently, this second strategy is generating a great deal of interest.

Stem cells do not only create new cells

For years we thought of stem cells primarily as cells capable of transforming into other tissues. But today we know that a huge part of their activity depends on the molecules they release. These signals can influence the cells of the dermal papilla, fibroblasts, blood vessels, the immune response, and the molecular pathways involved in the hair cycle.

This is where the secretome comes in

The secretome is everything a cell releases into its surroundings. It can include growth factors, cytokines, proteins, lipids, extracellular vesicles, microRNA, and other molecules. When we culture cells in the laboratory, many of these substances remain in the culture medium. That liquid is called conditioned medium.

What does that conditioned medium contain?

It depends enormously on the cell used. One of the most studied products in alopecia comes from stem cells derived from adipose tissue. These cells can release molecules related to angiogenesis, cell survival, proliferation, dermal papilla activity, and the entry of the follicle into the anagen phase. Among the molecules studied, we find various growth factors.

What signals are important for hair?

There are many. For example, VEGF (related to vascularization), IGF-1 (involved in cell survival and growth), FGF (related to proliferation and follicular activity), PDGF (involved in repair and cell signaling), and HGF (related to growth and remodeling). But the follicle does not respond to a single molecule: hair growth depends on a complete network of signals.

One of the most important pathways: Wnt/beta-catenin

This molecular pathway appears constantly in hair research. Proper activation of Wnt/beta-catenin is involved in activating follicular stem cells and in the transition to the anagen phase. Put simply, it helps tell the follicle 'it's time to grow again.' Exosomes and other stem cell-derived products are being studied precisely for their ability to modulate this pathway. A 2026 systematic review describes Wnt/beta-catenin and Sonic Hedgehog signaling, as well as TGF-beta modulation, among the proposed mechanisms of exosomes in androgenetic alopecia.

And what are exosomes?

Exosomes are small extracellular vesicles. We can think of them as small packages that one cell sends to another. Inside, they carry proteins, lipids, RNA, microRNA, and other molecules. This is why they can modify the behavior of a recipient cell.

An exosome is not a stem cell

This is extremely important: a stem cell is not the same as an exosome. The exosome is a product secreted by the cell. Nor is it the same as conditioned medium, which can contain exosomes, other types of vesicles, growth factors, proteins, and many other substances. This is why not every 'stem cell' product is equivalent.

What do exosomes theoretically do in the follicle?

Preclinical studies suggest several mechanisms: they may stimulate dermal papilla cells, promote entry into the anagen phase, modulate inflammation, influence vascularization, activate regenerative pathways, and reduce certain signals that drive miniaturization. They can also carry microRNA capable of modifying the gene expression of recipient cells. That is biologically fascinating. But the important question is: does it actually work in people?

What do clinical studies say?

Here we already have some interesting data. A systematic review on the use of stem cells in androgenetic alopecia identified 14 studies. Overall, stem cell-based therapies showed favorable signals in hair density, regeneration, and growth. However, the authors stressed that the results should be interpreted with caution until larger and more representative studies become available.

We also have randomized trials

A 2024 systematic review specifically analyzed 12 randomized clinical trials. Cell sources included adipose tissue, hair follicles, bone marrow, umbilical cord, and other sources. Overall, the studies showed increases in hair density and regeneration, although the protocols varied widely and some effects may have been temporary.

What about conditioned medium?

Here we even have a meta-analysis. Ten clinical trials were analyzed. In eight of them, involving 221 patients, stem cell-derived conditioned medium was associated with a mean increase of approximately 15 hairs per cm² in density and an increase in hair shaft thickness. When the authors analyzed only the randomized trials, the effect on density remained statistically significant. That is interesting — very interesting. But it does not yet mean 'we have cured androgenetic alopecia.'

Why? Because 221 patients is still a small number, and because the studies used different cells, concentrations, application methods, frequencies, and durations. We do not yet have a universal protocol.

And what about exosomes specifically?

A systematic review published in 2025 brought together 11 clinical studies, but only two were randomized trials; the remainder included retrospective studies, studies without a control group, case series, and individual case reports. The initial results suggested improvements in density and thickness, but the authors concluded that safety and efficacy still required confirmation.

And in 2026 we have more recent data

A systematic review published in June 2026 identified 39 preclinical and clinical studies on exosomes and androgenetic alopecia. The initial clinical studies described approximate increases in hair density of 8 to 20% and improvements in thickness. Once again, however, these came with small sample sizes, many retrospective studies, a lack of controls, and outcomes measured in different ways. So: promising, yes; a fully established standard treatment, not yet.

What happens when we combine these therapies with minoxidil?

This is especially interesting. A randomized double-blind trial studied the combination of conditioned medium derived from adipose stem cells with minoxidil in male androgenetic alopecia. The rationale is very compelling: not necessarily to replace the classic treatment, but to try to enhance it with regenerative signaling. And this is probably one of the most reasonable short-term paths: complementing treatments that we already know work.

Because minoxidil and finasteride are still here

This is very important. Regenerative medicine does not erase decades of evidence. In androgenetic alopecia we still have tools such as minoxidil, finasteride in certain men, dutasteride in selected situations, anti-androgenic treatments in certain women, hair transplantation, and PRP in selected contexts. Stem cell-derived products are a possible additional tool, not an excuse to abandon effective treatments.

Can an exosome make a dead follicle grow back?

No. If the follicle has been destroyed and replaced by scar fibrosis, there is no magic cell that will make it reappear simply by applying a product. This is crucial in scarring alopecias.

That is why diagnosis always comes first

If you have lichen planopilaris and someone offers you 'exosomes to make your hair grow' without first controlling the inflammation, we have a problem. Because your priority is not to stimulate growth: your priority is to stop follicular destruction.

What about alopecia areata?

Research is ongoing there too. But alopecia areata is fundamentally an autoimmune disease: the immune system attacks the follicle. Therefore, any regenerative therapy must be understood within that context. Stimulating the follicle is not enough if the immune system continues to attack it.

What about telogen effluvium?

It does not make much sense to automatically sell exosomes for that either. Because if the problem was surgery, childbirth, illness, rapid weight loss, a deficiency, or a medication, the priority is to identify and correct the trigger. The follicle may spontaneously recover its cycle.

So, for which type of alopecia is this technology most interesting today?

The majority of clinical research focuses on androgenetic alopecia, and that makes sense: because in this condition we have miniaturized follicles that are still present. There lies a potential target for regenerative signaling.

How are these products administered?

It depends on the study. Topical application, microneedling, intradermal injections, and combinations of these have all been used. Microneedling creates microchannels and also triggers a reparative response on its own; that is why it can be used to facilitate the penetration of certain products.

Does microneedling + exosomes automatically mean a better result?

Not necessarily. We need to demonstrate that the added product genuinely improves the outcome compared with microneedling alone, because microneedling can already have biological activity on its own. This is one of the things that many commercial campaigns forget to explain.

And what is the difference with PRP?

PRP uses your own platelets. When platelets are activated, they release growth factors; therefore, PRP also works through biological signalling. Cell-derived products may contain a different profile of factors, cytokines, vesicles and microRNA. They are not equivalent, but conceptually both aim to modify the microenvironment of the follicle.

What is the difference with the 'stem cells' sold by some clinics?

Here you need to ask exactly what is being administered. Because 'stem cell treatment' can mean live cells, stromal vascular fraction, processed adipose tissue, conditioned medium, secretome, exosomes or a cosmetic product containing extracts. These are completely different things.

And this is where regulation comes in

This point is very important. The FDA warns that there is very widespread marketing of unapproved regenerative products, including stem cells, adipose-tissue-derived products and exosomes, and notes that there are currently no FDA-approved exosome products. It has also received reports of serious adverse events related to unauthorised regenerative products. This does not mean that 'exosomes do not work'; it means we should not buy biology based on marketing.

'Exosomes' written on a box proves nothing

To know that a product genuinely contains well-characterised exosomes, we need to know its cellular origin, production method, purification, concentration, size, markers, sterility, stability and biological content. Two products marketed as 'exosomes' can be completely different.

And what about safety?

Initial clinical studies generally report few significant adverse effects, which is reassuring. However, we still have relatively few patients and short follow-up periods. An absence of major complications in 50 or 100 people does not demonstrate perfect long-term safety. Especially with biological products, we need vigilance.

Could they cause tumours?

This question comes up a lot. It is not correct to say that 'exosomes cause cancer', but we should not oversimplify either. Growth factors and regenerative pathways have complex functions. That is why any biologically active product requires controlled manufacturing, characterisation, regulation and medical indication. The answer is not to fear biology: it is to control it properly.

The most fascinating part: perhaps the future is not about 'putting in cells'

This is probably one of the most interesting ideas. We may not need to transplant whole cells; perhaps we can use the signals they produce. This would avoid some of the problems related to cell viability, engraftment, rejection and unpredictable behaviour. That is why the field of cell-free therapies is growing so rapidly.

Will we ever be able to create new follicles?

This would be the true paradigm shift. Right now, we are mainly trying to rescue, thicken, or reactivate existing follicles. But tissue engineering is investigating follicular neogenesis — that is, manufacturing new follicles — using combinations of dermal papilla cells, epithelial cells, matrices, organoids, and molecular signals. This is still far from being a routine therapy, but scientifically it is probably one of the most fascinating areas of regenerative dermatology.

Will this ever replace hair transplantation?

Perhaps in the future, but not today. Hair transplantation remains a way of relocating functional follicles from a resistant area to a depleted one. Regenerative medicine is attempting something different: modifying the behaviour of the follicle that is already there. These are different strategies.

And something I consider fundamental: treating early

In androgenetic alopecia, the further the condition progresses, the more miniaturised the follicle becomes. That is why a regenerative therapy will probably make more sense when a viable follicle still exists than when an area has been completely bare for years. This is something we also see with classical treatments.

How do I know if I still have recoverable follicles?

Through a dermatological examination, trichoscopy, analysis of miniaturisation, distribution, and clinical history. And in uncertain cases, with a biopsy. Not with a simple commercial camera that tells you 'your hair is weakened.'

Before the technology, diagnosis first

Before talking about exosomes, PRP, stem cells, laser, microneedling, or mesotherapy, one key question must be answered: what type of alopecia do you have? Because the same treatment can be meaningful in one condition and completely useless in another.

What I want you to remember

Stem cells and their derivatives represent one of the most interesting areas of research into hair growth. But we must distinguish between live stem cells, secretome, conditioned medium, growth factors, and exosomes: they are not the same thing. Clinical studies show real signs of improvement, particularly in androgenetic alopecia. A meta-analysis of conditioned medium found significant increases in hair density and thickness, although with few patients and highly heterogeneous protocols. Reviews of exosomes from 2025–2026 also show favourable initial results, but still with few randomised trials and considerable heterogeneity. That is why my position is: promising, yes; miracle treatment, no.

I am Dr. Florian Vallecillo, and if there is one single idea I want to leave you with today, it is this: the future of hair regeneration will probably not consist solely of 'stimulating hair growth,' but rather of learning to control the signals that determine whether a follicle grows, miniaturizes, or remains dormant. Stem cells, their growth factors, and their extracellular vesicles may help us understand — and perhaps modify — those signals. But before we talk about technology, we first need to know which condition we are treating: a miniaturized follicle may still have potential, an inflamed follicle requires us to halt the inflammation, and a follicle destroyed by scarring alopecia cannot be restored simply by applying 'exosomes.' Regenerative hair medicine may be part of the future, but for it to be true medicine it requires diagnosis, science, well-characterized products, regulation, and realistic expectations. Because in trichology, the word 'regenerative' must never replace diagnosis.